AI eye scans could help underserved youth with diabetes avoid vision loss
NCT ID NCT05463289
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study tests whether using an AI-driven retinal camera during regular diabetes checkups can increase the number of young people screened for diabetic retinopathy, a leading cause of blindness. Researchers will enroll 500 youth with type 1, type 2, or cystic fibrosis-related diabetes, focusing on underserved groups. The goal is to see if this point-of-care approach is accurate and helps close racial gaps in screening rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins Pediatric Diabetes Center
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IDx-DR autonomous AI software for diabetic retinopathy screening
What this could lead to
If successful, this could make diabetic retinopathy screening faster and more accessible for young people with diabetes, especially those in underserved communities.
What could go wrong
This is an early-stage implementation study, not a treatment trial. The AI's accuracy in youth is still being tested, and it may not work as well as in adults.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.